Paradigms Updated Corporate Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm Raises A$9 Million
- PAR reports pain reduction in oa patients
- Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
- Appendix 4E and 2018 Annual Report
- PAR achieves 60 per cent reduction in osteoarthritis pain
Later from Paradigm Biopharmaceuticals
- Paradigm Agreement With USA Past Players Network
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm receives $2.32m R&D tax incentive refund
- Paradigm in-licenses treatment for rare joint disease
- Paradigms AGM Presentation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals